Servizi di vigilanza

Offriamo servizi di vigilanza durante tutto il ciclo di vita dei prodotti

Ricerca clinica e sviluppo

Gestione della sicurezza clinica di medicinali, dispositivi medici e integratori alimentari

Registrazione e domanda di commercializzazione

Sviluppo dei documenti di sicurezza richiesti per le integrazioni alla domanda di commercializzazione

Post-commercializzazione

Garanzia GVP e controllo della sicurezza durante tutto il ciclo di vita del prodotto.

SERVIZI DI VIGILANZA

Attività di vigilanza in Spagna, Italia e Portogallo, con la possibilità di svolgere attività in altri paesi attraverso la rete Leon Research.

Intendiamo la vigilanza come il processo di monitoraggio e valutazione della sicurezza e del rapporto rischio/beneficio dei prodotti durante tutto il loro ciclo di vita, comprese le fasi cliniche e la fase di commercializzazione.
Allo stesso modo, il monitoraggio della sicurezza dei dispositivi medici è essenziale per prevenire e ridurre il ripetersi di incidenti legati al loro utilizzo.

Come lavoriamo alla León Research

Forniamo un servizio di vigilanza di alta qualità creando un piano specifico per il sistema di sicurezza da seguire in ogni progetto, adattato alle linee guida della Buona Pratica di Farmacovigilanza incluse nel Quadro Giuridico dell’Unione Europea, seguendo i più elevati standard di qualità per garantire la conformità ai requisiti di sicurezza.

Principali servizi di vigilanza

EU-QPPV

QPPV locale in Spagna, Italia e Portogallo

Responsabile EV per le sperimentazioni cliniche

Elaborazione dei casi e redazione di relazioni narrative

Ricerche nella letteratura scientifica globale e locale

Segnalazione di ICSR e SUSAR a EudraVigilance

Redazione di documenti medici e sulla sicurezza

Preparazione di relazioni aggregate (PSUR, DSUR e ASR)

Farmacovigilanza dei radiofarmaci

Farmacovigilanza dei medicinali veterinari

Contattaci

RICERCA CLINICA E SVILUPPO

Responsabile EV
Creazione e mantenimento del piano di gestione della sicurezza
Elaborazione dei casi, compresa la revisione narrativa e medica
Preparazione dei moduli CIOMS e segnalazione SUSAR
Creazione e manutenzione del database globale sulla sicurezza
Preparazione e presentazione del DSUR

REGISTRAZIONE E DOMANDA DI COMMERCIALIZZAZIONE

Preparazione del sistema di farmacovigilanza, compreso il PSMF
Sistema di gestione dei rischi
EU-QPPV
Supporto per le domande di autorizzazione all’immissione in commercio (MAA)
Preparazione di fascicoli pronti per l’autorità di regolamentazione
Coordinamento con le autorità competenti

POST-COMMERCIALIZZAZIONE

Creazione e mantenimento dell’accordo PV
EU-QPPV e vice
Supporto PV locale
PSM e accordo PV
Segnalazione ICSR
Ricerche nella letteratura scientifica globale e locale
Rapporti di sicurezza aggregati
Gestione dei segnali
Informazioni normative
Sistema di qualità, SOP e audit

Vigilance Services Glossary

ADR (Adverse Drug Reaction)

AESI (Adverse event of special interest)

Aggregate Reports

AMP (Authorised Medicinal Product)

CIOMS Form
Standardized document including the minimum required information for the appropriate reporting of adverse drug reactions.

The Council for International Organizations of Medical Sciences (CIOMS) create this Form with the purpose of providing an international reference to unify the reporting procedure between different countries.

Different national and international regulatory authorities have created their own reports based on the CIOMS Form I, firstly established in 1987.

Complianze On Pharmacovigilance

DEPUTY QPPV (Qualified Person Responsible for Pharmacovigilance)

DSUR (Development Safety Update Report)

Eudravigilance

FDA Complianze

ICSR (Individual Case Safety Report)

IMP (Investigational Medicinal Product)

LRPV (Local Responsible for Pharmacovigilance)
Is the person responsible for some or all (if required by the country specifications), of the pharmacovigilance tasks in a country or territory.

For some territories, this person needs to be formally nominated.

Unless defined otherwise, this person should have a university degree in natural sciences or human/veterinary medicine to be habilitated to act as a responsible person for pharmacovigilance activities.

MAH (Marketing Authorization Holder)
Refers to the individual, company, institution, organization or other legal entity in whose name the marketing authorization has been granted.

The marketing authorization may have been granted for a medicine in one, several or all European Union Member States.

The MAH is the responsible for all aspects of the product, including quality and compliance with the conditions of marketing authorization.

Medication Error

Medication Interaction
Refers to any interaction with the medication, and may be classified by the interaction agent itself:

Drug-drug interactions: These are the most common type of drug interaction. The more medications and types of medications you take, the greater the chance for your drug interacting with another medicine. Drug-drug interactions can decrease how well your medications work, may increase minor or serious unexpected side effects, or even increase the blood level and possible toxicity of a certain drug.

Drug-food/beverage interactions: Certain medications can interact with foods or beverages.

Drug-disease interactions: Existing medical condition can affect the way a drug works.

Off-Label

Pharmacovigilance
From the etymological perspective, pharmacovigilance can be divided into two words, pharmaco from the greek “pharmakon” meaning drug and vigilance from the latin “vigilare” meaning to keep watch.

So in general terms, pharmacovigilance is the process to keep a continued vigilance over the marketed and unmarketed (under clinical trials) medicinal products in order to detect, assess, understand and prevent adverse reactions.

PSMF (Pharmacovigilance System Master File)

PSUR (Periodic Safety Update Report)

QPPV (Qualified Person Responsible For Pharmacovigilance)

RP EudraVigilance (Responsible Person)

Risk Management Plan

SAE (Serious Adverse Event)
The acronym SAE refers to a serious adverse event, which is defined as any noxious medical occurrence associated with the use of a pharmaceutical product that is life-threatening or is considered a medically important event or can cause persistent/significant disability, birth defect, hospitalisation, or prolong an existent hospitalisation, or ultimately results in death.

Please note that SAE does not necessarily need to be considered drug-related.

Safety Database
Means a database where it is collected all the Adverse Events, Serious Adverse Events, Serious Adverse Drug Reactions, and pregnancy report occurred during a clinical Trials or in case of Authorised Medicinal Product, all the adverse events reported directly by a health care professionals or users to the Marketing Authorisation Holder or Competent Authority website (special tab for this purpose).

Safety reporting of medical devices

SMP (Safety Management Plan)
It is the procedure created to regulate all safety communication between the Sponsor and the Contract Research Organizations (CROs).

This procedure ensures the safety reporting of serious adverse events to sites, institutional review boards (IRB) and competent authorities is performed correctly, timely and accordingly with the regulatory requisites.

It also ensures the integrity of the clinical study results and the use of the authorized medicinal products.

SDEA (Safety Data Exchange Agreement)
Written legal agreement between the Marketing Authorization Holder and any subcontractor (pharmacovigilance, manufacturer, licensing partners) that assure any safety information concerning licensed medicinal products will be reported to the MAH so legal reporting requirements can be met.

For pharmacovigilance subcontractors, within this agreement, responsibilities concerning pharmacovigilance activities are clearly stated, granting that an appropriate pharmacovigilance system is in place and that all legal requirements are fulfilled.

Signal Detection

Signal
Information provided by marketing experience, investigations or different sources that suggest a plausible causal relationship, or provide new information on a previously known relationship, between a medicinal product and an event, both adverse or beneficial.

Safety signals are especially relevant as they can lead to new medicinal product risk identification so depending on its seriousness and frequency, further MAH actions may be required to confirm the hypothesis.

SUSAR (Suspected Unexpected Serious Adverse Reaction)
This term is used in clinical trials to refers to a serious adverse reaction, i.e. any untoward medical occurrence that results in death, is life-threatening, causes persistent or significant disability, congenital anomaly, hospitalization, or prolonged an existing hospitalization, and that was reported as having a reasonable causal relationship with the experimental medicinal product and is not listed in the applicable product information.

USADE (Unanticipated Serious Adverse Device Effect)

Links